Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:44 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer
NCT05191797 · University of Washington · PHASE1/PHASE2 · terminated · last registry update 2024-09-26 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Closed per SRC Low Accrual Policy” | – | Registry record, University of Washington |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against KDM1A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-09-22Results posted on the registry: Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA), Bomedemstat (NCT05223920)
- 2025-05-20Results posted on the registry: The University of Texas Health Science Center at San Antonio, IMG-7289 (NCT04081220)
- 2024-06-13Phase 3 first posted: Merck Sharp & Dohme LLC, Bomedemstat + Hydroxyurea (NCT06456346)
- 2024-04-08Phase 3 first posted: Merck Sharp & Dohme LLC, Bomedemstat (NCT06351631)
- 2024-04-02Results posted on the registry: Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA), Bomedemstat (NCT04254978)
- 2024-01-10Results posted on the registry: Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA), Bomedemstat (NCT03136185)
- 2023-10-12Phase 3 first posted: Merck Sharp & Dohme LLC, Bomedemstat + Anagrelide (NCT06079879)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision